Hypertrophic Cardiomyopathy Clinical Trials in San Francisco, California
6 recruitingSan Francisco, California
Showing 1–6 of 6 trials
Recruiting
Phase 2
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.165 enrolled56 locationsNCT07023614
Recruiting
Phase 2Phase 3
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
PediatricSymptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics55 enrolled38 locationsNCT06412666
Recruiting
Phase 1Phase 2
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
Hypertrophic Cardiomyopathy
Tenaya Therapeutics30 enrolled10 locationsNCT05836259
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Non-obstructive Hypertrophic CardiomyopathyObstructive Cardiomyopathy, Hypertrophic
Lexicon Pharmaceuticals500 enrolled107 locationsNCT06481891
Recruiting
Not Applicable
Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy
University of California, San Francisco70 enrolled1 locationNCT05818605
Recruiting
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb1,600 enrolled99 locationsNCT05489705